Geron (GERN) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Geron (GERN) over the past year, losing 1.5% versus a loss of 11.9%. Over five years, GERN leads with a -13.1% price change compared with -88.3% for GYRE. Geron is the larger company by market cap ($787.0 million vs $746.5 million), about 1.1 times the size.
On valuation, Geron trades at a lower forward P/E (30.6x vs 117.3x for Gyre Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GERN | GYRE |
|---|---|---|
| Share price | $1.23 | $7.04 |
| Market cap | $787.03M | $746.48M |
| 1-day change | +0.41% | +4.14% |
| YTD return | -7.20% | -0.28% |
| 1-year return | -11.87% | -1.54% |
| 5-year return | -13.12% | -88.27% |
| Forward P/E | 30.63 | 117.33 |
| EPS (TTM) | $-0.11 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.01 | $9.42 |
| 52-week low | $1.04 | $5.44 |
| Distance from 52-week high | -39.05% | -25.27% |
| Analyst consensus | none | none |
| Avg. price target upside | +246.94% | +165.20% |
| Average volume | 10.06M | 105.93K |
| Shares outstanding | 642.47M | 106.03M |
| Employees | 258 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed GERN by 10.3 percentage points over the past year.
About Geron
GERN stock →Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
GERN vs GYRE FAQ
Which is bigger, Geron or Gyre Therapeutics?
Geron (GERN) is larger, with a market capitalization of $787.03M compared with $746.48M for Gyre Therapeutics (GYRE).
Which stock has performed better over the past year, GERN or GYRE?
GYRE returned -1.54% over the past 12 months, compared with -11.87% for GERN (price return, excluding dividends). Past performance does not predict future results.
Are Geron and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.